Is angiogenesis a hallmark of prostate cancer? by Gianluigi Taverna et al.
OPINION ARTICLE
published: 06 February 2013
doi: 10.3389/fonc.2013.00015
Is angiogenesis a hallmark of prostate cancer?
Gianluigi Taverna1, Fabio Grizzi2*, Piergiuseppe Colombo3 and Pierpaolo Graziotti 1
1 Department of Urology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
2 Laboratory of Molecular Gastroenterology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
3 Department of Pathology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
*Correspondence: fabio.grizzi@humanitasresearch.it
Edited by:
Richard J. Cote, University of Miami Miller School of Medicine, USA
Reviewed by:
Richard J. Cote, University of Miami Miller School of Medicine, USA
In vertebrate organogenesis, the blood
vessels constitute the first organ sys-
tem that arises and reaches a functional
state (Persson and Buschmann, 2011).
Angiogenesis, the development of new
branching vessels from existing vascu-
lature, is a complex process observed
in fetal growth, wound healing and
endometrial hyperplasia associated with
the menstrual cycle (Carmeliet, 2003).
Under these conditions, it is highly reg-
ulated: i.e., “turned on” for brief periods
of time and then completely inhibited.
However, many human diseases, includ-
ing tumors, are driven by persistently up-
regulated angiogenesis (Carmeliet, 2003,
2005; Hanahan and Weinberg, 2011). In
some non-malignant diseases, such as
lobular capillary hemangioma or keloid
formation, angiogenesis is self-limited;
however, this is not true of tumor angio-
genesis, which, once begun, continues
indefinitely until the entire tumor is erad-
icated or the host dies. Without blood ves-
sels, tumors cannot grow beyond a critical
size. Angiogenesis is regulated by a balance
of pro- and anti-angiogenic molecules
(Hanahan and Weinberg, 2011), secreted
from cancer cells, endothelial cells and
stromal cells (Fukumura et al., 1998), the
relative contributions of which are likely
to change with tumor type and site, as
well as with tumor growth, regression and
relapse. It is also ascertained that angio-
genic vessels have a disorganized and irreg-
ular structure, and that the blood flow is
abnormal. This is in contrast to the orga-
nized, regular structure and normal blood
flow seen in mature vessels. Angiogenesis
can be depicted as a non-linear dynamic
process that is discontinuous in space and
time, but advances through qualitatively
different states. The term state defines the
configuration pattern of the process at any
given moment, and a dynamic process can
be represented as a set of different states
and a number of transitions from one state
to another over a certain time interval. The
continuum of these states generates a com-
plex ramified structure that irregularly fills
the surrounding environment. The main
feature of the newly generated vasculature
is the structural diversity of the vessel sizes,
shapes, and connecting patterns. This is
mainly due to the heterogeneous distri-
bution of angiogenic regulators, such as
vascular-endothelial growth factor, basic
fibroblastic growth factor and angiopoi-
etin, leading to hypoxic and acidic tumoral
regions (Karlou et al., 2010). Moreover,
although it is commonly believed that the
endothelial cells making-up tumor ves-
sels are genetically stable, tumor vascula-
ture seems to be much more unpredictable
(Streubel et al., 2004). These conditions
all reduce the effectiveness of treatments,
modulate the production of pro- and anti-
angiogenic molecules, and select a subset
of more aggressive cancer cells with higher
metastatic potential.
The significance of angiogenesis in
prostate cancer (PC) still remains contro-
versial (Russo et al., 2012). While there are
currently no markers of the net angiogenic
activity of PC that can help investigators
to design specific anti-angiogenic treat-
ment strategies, it is reasonable to assume
that the quantification of various aspects
of tumor vasculature may provide an indi-
cation of angiogenic activity. One often-
quantified parameter of PC vasculature is
microvessel density (MVD), which is used
to allow a histological assessment of tumor
angiogenesis. The results of studies carried
out over the last decade have suggested the
value of using MVD as a prognostic index
in PC, and it has also assumed that MVD
may reveal the degree of angiogenic activ-
ity in PC. MVD has, however, a number of
limitations. The conflicting MVD results
in PC are likely due to the differences in
study designs: variability in patient pop-
ulation size, tumor topography, approach
to selection of representative tumor areas,
choice of endothelial marker, and actual
counting method. The selection of the
tumor area for MVD assessment has
been based on two different approaches:
(1) analysis of a few microscopic “hot
spots” containing the maximal vascular
density, and (2) selection of random rep-
resentative areas of the tumor. The first
approach is the most applied due to its
simplicity, although there is no agreement
among investigators regarding optimal
microscope magnification, the number of
vascular hot spots, and cutoff values for
low vs. high MVD. The second approach
of MVD assessment within larger repre-
sentative areas or whole tissue may be
more objective but involves more tedious
examination.
Despite its importance as a prognos-
tic indicator in untreated tumors, MVD
has not been shown to be a valid mea-
sure to guide or evaluate anti-angiogenic
treatment (Hlatky et al., 2002). MVD
does not appear to be predictive of
tumor response under anti-angiogenic
treatment and therefore may not be use-
ful for stratifying patients for clinical tri-
als (Rubin et al., 1999; Eberhard et al.,
2000; Hlatky et al., 2002; Preusser et al.,
2006; Erbersdobler et al., 2010). LowMVD
does not portend a poor response to
anti-angiogenic therapy (Vartanian and
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Weidner, 1995; Eberhard et al., 2000;
Hlatky et al., 2002). Tumor MVD may not
vary in accordance with the tissue or blood
levels of any single pro-angiogenic factor.
Rapid tumor growth does not imply high
MVD. The MVD of a tumor need not be
higher, and is often lower, than that of
its corresponding normal tissue, which is
experiencing no net growth. The efficacy
of anti-angiogenic agents cannot be sim-
ply visualized by alterations in MVD dur-
ing treatment (Pluda, 1997; Hlatky et al.,
2002). In addition, MVD is substantially
limited by the complex biology character-
izing tumor vasculature (Aird, 2012), and
the highly irregular geometry that the vas-
cular system assumes in real space, which
cannot be measured using the principles
of Euclidean geometry because it is only
capable of interpreting regular and smooth
objects that are almost impossible to find
in Nature (Grizzi et al., 2007). Quantitative
descriptors of its geometrical complex-
ity can be, however, abstracted from the
Fractal geometry introduced by Benoit
Mandelbrot in 1975 (Baish and Jain, 2000;
Grizzi et al., 2005). The complex geom-
etry of tumor vasculature and its struc-
tural and functional heterogeneity mean
that vascular network cannot be measured
on the basis of MVD estimates alone.
Tetiakova et al. applying an automated
image analysis to conventional and tis-
sue microarray sections in large represen-
tative areas demonstrated that there was
no significant increase in MVD param-
eters in PC vs. matched normal periph-
eral zone prostatic tissue (Tretiakova et al.,
2012). Paradoxically, several morpholog-
ical indexes were higher within normal
glandular prostatic tissue. Deering et al.
also reported no increase in MVD counts
between benign prostatic hyperplasia and
PC by computer-assisted image analysis
(Deering et al., 1995). Barth et al. demon-
strated that direct stereologic assessment
of vascular surface density quantitating
the vessel area per tissue volume showed
no significant difference between normal
and PC tissue from grade 2 and grade
3 tumors (Barth et al., 1996). Another
study of two-dimensional vascularity of
PC by Taverna et al. (2009) divided all
cases in two groups with 56% of cases
showing increase of vascular surface in
PC vs. non-tumoral areas and 44% show-
ing a decrease of vascular surface in PC.
The second group of patients with lower
tumoral vascular surface had a poorer out-
come indicating that tumor progression
is independent of angiogenesis (Taverna
et al., 2009). These findings parallel recent
data by Steiner et al. (2012) who showed
no significant difference for CD31 mRNA
levels from normal prostate and matched
PC (P = 0.78). No significant correlation
for CD31 between mRNA and protein lev-
els by immunohistochemistry implies that
in the typical slow growth of PC, the
angiogenesis dynamics are also quite low
(Steiner et al., 2012).
A non-invasive imaging technique that
could reflect MVD would hold great
promise in tumor detection and character-
ization (Jain et al., 1997; Jiang et al., 2011).
An imaging method that could indicate
an increase in MVD could have value
in choosing targets for prostate biopsies
(Jiang et al., 2011). This will lead to a
change in biopsy strategies, bringing about
a higher detection rate of PC, and hence,
a more appropriate therapeutic strategy
(Jiang et al., 2011). Preliminary data sug-
gested that the haemodynamic indices
obtained from contrast-enhanced ultra-
sound imaging were different between
low- and high-grade PCs (Jiang et al.,
2011). The microvessels that prolifer-
ate in PC are below the resolution of
conventional Doppler imaging; only the
larger vessels are visualized by this imag-
ing technique (Halpern, 2006). Franiel
et al. attempt to determine whether estab-
lished histologic parameters of prognos-
tic importance, including MVD, correlate
with parameters obtained at pharmacoki-
netic dynamic contrast material–enhanced
(DCE) dual-contrast-enhanced magnetic
resonance (MR) imaging (Franiel et al.,
2009). They found that blood volume
and interstitial volume did not reliably
correlate with the histologic parameters,
mainly due to the heterogeneous vascu-
larization of both normal prostate tissue
and PC (Mucci et al., 2009). Variability
over patients is large with patients showing
both increased and decreased vascularity
in the tumor (van Niekerk et al., 2012).
Thus, determination of vascularization in
a two-dimensional histological slide is not
representative of the vascularity of the tis-
sue as a whole (Rubin et al., 1999; Grizzi
et al., 2005). The antibody used also seems
to play a role, since it has been shown
that MVD immunohistochemically deter-
mined with CD31 antibody staining was
significantly lower than that obtained with
CD34 antibody staining (De La Taille et al.,
2000). Moreover, correlation of histologic
and MR data sets was limited by the fact
that the paraffin sections are 4µm-tick,
whereas the corresponding T2-weighted
images have a slice thickness of 3mm
and the dynamic susceptibility weighted
MR DCE-MR sequence is acquired with
a slice thickness of 5mm (Franiel et al.,
2010). Computer-based 3D prostate mod-
els may in the future enable the desired
detail correlation between histologic and
MR imaging findings (Franiel et al., 2010).
The lack of correlation between histologic
and functional parameters also raises the
question of the biologic significance of
functional parameters of tumor microcir-
culation quantified with dynamic imaging
enhanced with small-molecule contrast
medium (Cyran et al., 2012). Although,
Osimani et al. have recently shown that
blood volume and permeability surface-
area product measurements obtained with
perfusion computed tomography have
the highest correlation with immunohis-
tochemical markers of angiogenesis in
PC, before routine implementation, addi-
tional studies on larger series are needed
(Osimani et al., 2012).
Scientific knowledge develops through
the evolution of new concepts, and this
process is usually driven by new method-
ologies that provide previously unavailable
observation. The potential broad appli-
cability of the Fractal geometry makes
it possible to explore the range of the
morphological variability of neovascula-
ture that can be produced in nature,
thus increasing its diagnostic importance
in cancer research (Taverna et al., 2010;
Steiner et al., 2012). Prostate histologymay
remain the reference method for assess-
ing the status of neovascularity, but there
are still several open questions, including
whether angiogenesis is a canonic hall-
mark of PC, and the absence of a power-
ful method of quantifying the reversal of
neovascularity.
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